Ipca Laboratories
Ticker > Company >

Ipca Laboratories share price

Ipca Laboratories Ltd.

NSE: IPCALAB BSE: 524494 SECTOR: Pharmaceuticals & Drugs  1.72 L   690   96

1452.00
-21.30 (-1.45%)
BSE: 01 Aug 04:01 PM

Price Summary

Today's High

₹ 1480

Today's Low

₹ 1441

52 Week High

₹ 1757.65

52 Week Low

₹ 1200

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 36837.85 Cr.

Enterprise Value

₹ 37545.05 Cr.

No. of Shares

25.37 Cr.

P/E

56.61

P/B

5.35

Face Value

₹ 1

Div. Yield

0.28 %

Book Value (TTM)

₹  271.64

CASH

₹ 164.53 Cr.

DEBT

₹ 871.73 Cr.

Promoter Holding

44.72 %

EPS (TTM)

₹  25.65

Sales Growth

8.35%

ROE

9.83 %

ROCE

13.97%

Profit Growth

22.69 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Ipca Laboratories Ltd.

Glycinorm Glyree Larinate HCQS Zerodol CTD Revelol-AM Rapiclav Tazofast Folitrax Saaz Acera Solvin Cold

Index Presence

The company is present in 26Indices.

NFT150MOM50

Nifty Midcap150 Momentum 50
60474.45
  -756.75 (-1.23588954650571%)

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
44474.1
  -774.900000000001 (-1.71252403368031%)

NIFTY500

Nifty 500
22673.65
  -241.299999999999 (-1.05302433564114%)

NIFTYPHARMA

Nifty Pharma
22011.7
  -759.349999999999 (-3.33471666875265%)

NIFTYMIDCAP150

Nifty Midcap 150
21088.65
  -272.649999999998 (-1.27637362894579%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
19582
  -279.099999999999 (-1.40525952741791%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
17464.95
  -225.599999999999 (-1.27525712880605%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
15919.25
  -176 (-1.09349031546574%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
15820.45
  -189.549999999999 (-1.183947532792%)

NIFTYHEALTH

Nifty Healthcare Index
14468.7
  -411.549999999999 (-2.76574654323684%)

NFT500EQUAL

Nifty 500 Equal Weight
14040.1
  -206.65 (-1.45050625581272%)

NIFTYTOTALMCAP

Nifty Total Market index
12767.2
  -138.599999999999 (-1.0739357498179%)

NIFTYFULLMIDCAP100

NIFTY FULL MIDCAP 100
5987.56
  -42.7999999999993 (-0.709742038617911%)

MIDCAP

S&P Bse Mid Cap
45155.19
  -626.459999999999 (-1.36836483612975%)

BSE HC

S&P Bse Healthcare
44265.55
  -1106.48 (-2.43868303886777%)

BSE500

S&P Bse 500
35598.07
  -383.669999999998 (-1.06629084641264%)

MID150

S&P Bse 150 MidCap
15640.89
  -215.59 (-1.35963341170298%)

200EQW

BSE 200 Equal Weight
12676.09
  -169.700000000001 (-1.32105538079014%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
11810.67
  -175.52 (-1.4643518916353%)

BSE200

S&P Bse 200
11137.12
  -111.16 (-0.988239979801353%)

BSE1000

Bse 1000
10611.6
  -117.959999999999 (-1.09939270575866%)

LMI250

S&P Bse 250 LargeMidCap
10572.13
  -106.76 (-0.99972937262206%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
10319.66
  72.75 (0.709970127579918%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SHA500

S&P Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year8.35%
3 Year7.07%
5 Year8.87%

Profit Growth

1 Year22.69%
3 Year-8.89%
5 Year-0.05%

ROE%

1 Year9.83%
3 Year9.14%
5 Year14.27%

ROCE %

1 Year13.97%
3 Year12.84%
5 Year17.68%

Debt/Equity

0.1265

Price to Cash Flow

26.81

Interest Cover Ratio

16.3669

CFO/PAT (5 Yr. Avg.)

1.32717915623873

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 44.72 0.00
Mar 2025 44.72 0.00
Dec 2024 44.72 0.00
Sep 2024 46.30 0.00
Jun 2024 46.30 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy Interest coverage ratio of 16.3669.
  • The Company has been maintaining an effective average operating margins of 21.29788% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 48.9851 days.
  • Company has a healthy liquidity position with current ratio of 2.6664.
  • The company has a good cash flow management; CFO/PAT stands at 1.32717915623873.

 Limitations

  • The company has shown a poor profit growth of -8.88738097061157% for the Past 3 years.
  • The company has shown a poor revenue growth of 7.07263443986905% for the Past 3 years.
  • The company is trading at a high PE of 56.61.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 1510.64 1565.86 1810.94 1662.68 1638.44
Total Expenditure 1218.3 1212.62 1408.83 1251.59 1279.85
Operating Profit 292.34 353.24 402.11 411.09 358.59
Other Income 15.1 15.39 17 17.41 21.49
Interest 24.06 19.42 17.25 10.17 16.2
Depreciation 61.76 61.32 62.65 62.81 65.19
Exceptional Items -94.32 0 0 0 -281.54
Profit Before Tax 127.3 287.89 339.21 355.52 17.15
Tax 62.54 83.76 95.09 87.96 82.2
Profit After Tax 64.76 204.13 244.12 267.56 -65.05
Adjusted EPS (Rs) 2.55 8.05 9.62 10.55 -2.56

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 5114.11 5405.42 5774.72 6124.06 6635.38
Total Expenditure 3663.9 4220.01 4886.6 4959.25 5145.54
Operating Profit 1450.21 1185.41 888.12 1164.81 1489.84
Other Income 128.6 108.76 137.34 159.77 108.5
Interest 11.13 10.41 46.34 122.58 65.06
Depreciation 187.72 209.65 228.63 246.48 251.97
Exceptional Items 0 0 0 -133.36 -281.54
Profit Before Tax 1379.96 1074.11 750.49 822.16 999.77
Tax 239.19 213.74 244.79 291.75 349.01
Net Profit 1140.77 860.37 505.7 530.41 650.76
Adjusted EPS (Rs.) 44.97 33.91 19.93 20.91 25.65

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 25.37 25.37 25.37 25.37 25.37
Total Reserves 4727.35 5450.39 5851.93 6323.34 6866.25
Borrowings 9.13 395.18 651.78 542.19 482.43
Other N/C liabilities 182.69 213.77 240.11 248.2 277.34
Current liabilities 1065.59 1353.73 1677.78 1520.17 1417.6
Total Liabilities 6010.13 7438.44 8446.97 8659.27 9070.92
Assets
Net Block 1868.6 2153.09 2478.66 2523.7 2536.97
Capital WIP 180.85 293.37 114.31 165.59 484.05
Intangible WIP 1.15 3.78 8.71 9.61 5.6
Investments 474.01 619.39 733.41 2243.56 2041.32
Loans & Advances 183.45 119.21 227.77 186.16 164.4
Other N/C Assets 24.28 25.14 8.96 20.76 58.64
Current Assets 3277.79 4224.46 4875.15 3509.89 3779.94
Total Assets 6010.13 7438.44 8446.97 8659.27 9070.92
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 1379.96 1074.11 750.49 822.16 999.77
Adjustment 172.5 221.16 206.09 399.16 605.78
Changes in Assets & Liabilities -214.53 -271.39 20.96 -113.86 93.27
Tax Paid -241.87 -192.16 -215.25 -276.95 -324.75
Operating Cash Flow 1096.06 831.72 762.29 830.51 1374.07
Investing Cash Flow -559.56 -811.85 -709.61 -1355.18 -738.81
Financing Cash Flow -307.38 426.04 506.38 -464.88 -428.44
Net Cash Flow 229.12 445.91 559.06 -989.55 206.82

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 46.30 46.30 44.72 44.72 44.72
chandurkar investments pr... 5.50 5.50 5.50 5.50 5.50
kalpana jain 0.09 0.09 0.09 0.09 0.09
kaygee investments privat... 21.47 21.47 21.47 21.47 21.47
kaygee laboratories priva... 6.61 6.61 6.61 6.61 6.61
mexin medicaments private... 0.01 0.01 0.01 0.01 0.01
paschim chemicals pvt ltd... 4.01 4.01 4.01 4.01 4.01
pranay godha 0.67 0.67 0.67 0.67 0.67
prashant godha 0.62 0.62 0.62 0.62 0.62
premchand godha 2.29 2.29 2.29 2.29 2.29
sameer m chandurkar 0.79 0.79 0.79 0.79 0.79
usha m chandurkar 3.27 3.27 1.70 1.70 1.70
usha premchand godha 0.95 0.95 0.95 0.95 0.95
xbees traders llp 0.01 0.01 0.01 0.01 0.01
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 53.70 53.70 55.28 55.28 55.28
dsp midcap fund 6.43 5.97 6.12 6.19 6.50
hdfc life insurance compa... 1.95 1.93 1.93 1.93 1.93
hdfc mutual fund - hdfc m... 8.70 9.14 8.46 8.47 9.05
investor education and pr... 0.30 0.30 - 0.31 0.31
kotak emerging equity sch... 4.96 5.13 5.79 5.79 6.05
kotak funds - india midca... 1.36 1.36 1.34 1.29 1.26
llp 0.03 0.04 - 0.03 0.03
nippon life india trustee... 1.89 1.91 2.02 2.25 2.18
sbi life insurance co. lt... 2.01 2.20 2.42 2.85 3.30
investor education and pr... - - 0.31 - -
parag parikh flexi cap fu... 1.46 1.46 1.46 - -
abu dhabi investment auth... 1.00 - - - -
icici prudential balanced... 1.52 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CARE
Credit CRISIL
Credit CARE
Credit CRISIL
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
Research HDFC Securities
Research Dolat Capital
Research Motilal Oswal
Research ICICI Securities Limited
Research Prabhudas Lilladhar
Research Ipca Laboratories Ltd.

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY22
Concall Q4FY21
Concall Q4FY20
Concall Q3FY25
Concall Q3FY24
Concall Q3FY23
Concall Q3FY22
Concall Q3FY21
Concall Q2FY23
Concall Q2FY22
Concall Q2FY21
Concall Q2FY20
Concall Q1FY23
Concall Q1FY22
Concall Q1FY22
Concall Q1FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q3FY21
Presentation Q2FY21
Presentation Q2FY20
Presentation Q3FY20

Company News

Ipca Laboratories informs about annual report 11 Jul, 9:39 AM Ipca Laboratories informs about compliance certificate 10 Jul, 4:57 PM Ipca Laboratories informs about compliance certificate 10 Jul, 4:47 PM Ipca Laboratories informs about closure of trading window 24 Jun, 10:02 AM Ipca Laboratories - Quaterly Results 29 May, 1:54 PM Ipca Laboratories - Quaterly Results 29 May, 1:54 PM Ipca Laboratories - Quaterly Results 29 May, 1:54 PM Ipca Laboratories informs about general updates 2 May, 11:47 AM Ipca Laboratories informs about compliance certificate 7 Apr, 5:22 PM Ipca Laboratories informs about change in management 3 Mar, 5:39 PM Ipca Laboratories - Quaterly Results 13 Feb, 1:07 PM Ipca Laboratories - Quaterly Results 13 Feb, 1:07 PM Ipca Laboratories - Quaterly Results 13 Feb, 1:07 PM Ipca Laboratories informs about board meeting 27 Jan, 11:11 AM Ipca Laboratories informs about compliances-certificate 8 Jan, 5:24 PM IPCA Laboratories informs about change of name of RTA 3 Jan, 4:54 PM Ipca Laboratories informs about trading window closure 26 Dec, 2:51 PM Ipca Laboratories secures approval for voluntary closure of Mexico-based subsidiary 5 Dec, 12:21 PM Ipca Laboratories informs about newspaper publication 15 Nov, 5:14 PM Ipca Laboratories - Quaterly Results 14 Nov, 1:19 PM Ipca Laboratories - Quaterly Results 14 Nov, 1:19 PM Ipca Laboratories - Quaterly Results 14 Nov, 1:19 PM Ipca Laboratories informs about loss of share certificate 4 Oct, 12:41 PM Ipca Laboratories informs about notice of board meeting and trading window closure 23 Sep, 12:42 PM Ipca Laboratories informs about disclosure 20 Sep, 11:09 AM IPCA Laboratories informs about analyst meet outcome 19 Aug, 1:04 PM Ipca Laboratories launches Diulcus 17 Aug, 11:57 AM Ipca Laboratories - Quaterly Results 13 Aug, 1:13 PM Ipca Laboratories - Quaterly Results 13 Aug, 1:13 PM Ipca Laboratories - Quaterly Results 13 Aug, 1:13 PM IPCA Laboratories informs about disclosure 7 Aug, 12:12 PM Ipca Laboratories informs about media release 6 Aug, 3:08 PM IPCA Laboratories informs about details of loss of certificate 26 Jul, 4:24 PM Ipca Laboratories informs about board meeting 24 Jul, 2:12 PM Ipca Laboratories informs about loss of share certificate 18 Jul, 5:20 PM Ipca Laboratories informs about book closure 18 Jul, 11:53 AM IPCA Laboratories informs about business responsibility and sustainability report 17 Jul, 12:29 PM Ipca Laboratories informs about annual report 17 Jul, 10:15 AM Ipca Laboratories informs about trading window closure 21 Jun, 12:39 PM Ipca Laboratories informs about issuance of duplicate share certificate 14 Jun, 11:06 AM Ipca Laboratories informs about audio link of conference call 31 May, 1:01 PM Ipca Laboratories - Quaterly Results 29 May, 1:40 PM Ipca Laboratories - Quaterly Results 29 May, 1:40 PM Ipca Laboratories - Quaterly Results 29 May, 1:40 PM Ipca Laboratories informs about loss of share certificates 24 May, 12:19 PM Ipca Laboratories informs about loss of share certificates 6 May, 2:58 PM Ipca Laboratories informs about compliance certificate 22 Apr, 12:32 PM Ipca Laboratories enters into Technology Transfer Agreement with Omexa Formulary 27 Mar, 3:14 PM Ipca Laboratories informs about trading window closure 21 Mar, 3:17 PM Ipca Laboratories informs about press release 27 Feb, 4:34 PM

Ipca Laboratories Stock Price Analysis and Quick Research Report. Is Ipca Laboratories an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Ipca Laboratories and its performance over the period of time. Ipca Laboratories stock price today is Rs 1450.2.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Ipca Laboratories cash from the operating activity was Rs 1374.07 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Ipca Laboratories has a Debt to Equity ratio of 0.1265 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Ipca Laboratories , the EPS growth was 22.69 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Ipca Laboratories has OPM of 22.4529717966416 % which is a good sign for profitability.
     
  • ROE: Ipca Laboratories have a poor ROE of 9.83 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Ipca Laboratories is Rs 1450.2. One can use valuation calculators of ticker to know if Ipca Laboratories share price is undervalued or overvalued.
Last Updated on:
Brief about Ipca Laboratories

Ipca Laboratories Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Ipca Laboratories Ltd. is a leading pharmaceutical company in India that specializes in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs).  We will take a closer look at Ipca Laboratories Ltd. stock analysis page and explore various aspects of the company that can help long-term investors make informed investment decisions.

Ipca Laboratories Ltd Share Price

Ipca Laboratories Ltd.'s share price has been on a steady upward trend in recent years. The company's strong financial performance and growth prospects have attracted a lot of investor interest, leading to an increase in demand for its shares. Investors can track the company's share price on Ticker's stock analysis page, which provides real-time updates on the stock's performance.

Ipca Laboratories Ltd Balance Sheet

Ipca Laboratories Ltd.'s balance sheet is a reflection of its financial health and stability. The company has a strong balance sheet, with a healthy mix of debt and equity. Ticker pre-built screening tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach and DuPont analysis can help investors evaluate the company's financial performance and calculate its fair value. Investors can access the company's balance sheet on Ticker's stock analysis page, along with other financial data such as quarterly results and profit and loss statements.

Ipca Laboratories Ltd Annual Report

Ipca Laboratories Ltd.'s annual report provides a comprehensive overview of the company's performance over the past year. The report includes detailed information on the company's financials, operations, and growth prospects. Investors can download the company's annual report from Ticker's stock analysis page. The report can help investors gain a better understanding of the company's business model, competitive landscape, and growth potential.

Ipca Laboratories Ltd Dividend

Ipca Laboratories Ltd. has a track record of paying dividends to its shareholders. The company's dividend policy is based on its financial performance and growth prospects. Investors can access the company's dividend history on Ticker's stock analysis page. 

Ipca Laboratories Ltd Quarterly Result

Ipca Laboratories Ltd.'s quarterly results provide a snapshot of the company's financial performance over the past quarter. The results include information on the company's revenue, profits, and margins. Investors can download the company's quarterly results from Ticker's stock analysis page. Ticker pre-built screening tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach and DuPont analysis can help investors evaluate the company's financial performance and calculate its fair value.

Ipca Laboratories Ltd Stock Price

Ipca Laboratories Ltd.'s stock price is a reflection of its financial performance and growth prospects. The company's stock price is influenced by various factors such as market trends, investor sentiment, and the company's financials. Investors can track the company's stock price on Ticker's stock analysis page, which provides real-time updates on the stock's performance.

Ipca Laboratories Ltd Price Chart

Ipca Laboratories Ltd.'s price chart provides a visual representation of the company's stock price movement over a period. The chart includes information on the company's stock price, volume, and trends. Investors can access the company's price chart on Ticker's stock analysis page. The chart can help investors gain insights into the company's stock price movement and identify trends.

Ipca Laboratories Ltd News

Ipca Laboratories Ltd.'s news section provides updates on the company's latest developments and announcements. The section includes information on the company's product launches, partnerships, and collaborations. Investors can access the company's news section on Ticker's stock analysis page. The news section can help investors stay updated on the company's latest developments and make informed investment decisions.

Ipca Laboratories Ltd Concall Transcripts

Ipca Laboratories Ltd.'s concall transcripts provide a detailed account of the company's earnings conference call. The transcripts include information on the company's financial performance, growth prospects, and future plans. Investors can download the company's concall transcripts from Ticker's stock analysis page. The transcripts can help investors gain insights into the company's performance and future prospects.

Ipca Laboratories Ltd Investor Presentations

Ipca Laboratories Ltd.'s investor presentations provide a detailed overview of the company's business model, operations, and growth prospects. The presentations include information on the company's financials, product portfolio, and competitive landscape. Investors can download the company's investor presentations from Ticker's stock analysis page. The presentations can help investors gain a better understanding of the company's business model and growth potential.

Ipca Laboratories Ltd Promoters

Ipca Laboratories Ltd.'s promoters are the key drivers of the company's growth and success. The promoters have a significant stake in the company and are actively involved in its operations and decision-making. Investors can access information on the company's promoters on Ticker's stock analysis page. The information can help investors evaluate the promoters' track record and their contribution to the company's growth.

Ipca Laboratories Ltd Shareholders

Ipca Laboratories Ltd.'s shareholders are the owners of the company and have a stake in its financial performance and growth prospects. The company has a diverse shareholder base, including institutional investors and retail investors. Investors can access information on the company's shareholders on Ticker's stock analysis page. The information can help investors evaluate the company's shareholder base and their contribution to the company's growth.

Ipca Laboratories Ltd ROCE

Ipca Laboratories Ltd ROCE (Return on Capital Employed) measures the profitability and efficiency of the company's capital investments. It indicates how well the company generates returns from its capital employed. The ROCE can be obtained from the financials table or ratio section provided on this page.

Ipca Laboratories Ltd EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Ipca Laboratories Ltd provides insights into the company's operational profitability. This metric reflects the company's ability to generate earnings from its core business operations, excluding non-operating factors. For detailed EBITDA data, refer to the above financials table or ratio section.

Ipca Laboratories Ltd DPS

Ipca Laboratories Ltd DPS (Dividends Per Share) represents the amount of cash distributed to shareholders for each share held. It allows investors to assess the company's dividend policy and potential returns. The DPS information for Ipca Laboratories Ltd can be found in the above financials table or ratio section.

Ipca Laboratories Ltd EPS

The EPS (Earnings Per Share) of Ipca Laboratories Ltd is a crucial metric that shows the company's profitability on a per-share basis. It is obtained by dividing the company's earnings by the total outstanding shares. Investors can find the EPS data for Ipca Laboratories Ltd in the above financials table or ratio section on this page. 

Ipca Laboratories Balance Sheet Examination

Ipca Laboratories has demonstrated a strengthening financial position over the years, as shown by the data from March 2020 to March 2024.

Stability in Ipca Laboratories' Share Capital

Ipca Laboratories maintained a stable share capital at Rs. 25.37 Cr from March 2021 to March 2024, indicating confidence in the company's governance and future prospects.

Growth in Ipca Laboratories' Total Reserves

The total reserves of Ipca Laboratories have consistently grown from Rs. 3,652.27 Cr in March 2020 to Rs. 6,323.34 Cr in March 2024, underscoring the company's ability to accumulate retained earnings and strengthen its financial reserves.

Ipca Laboratories' Debt Management

Borrowings experienced fluctuations, reaching Rs. 651.78 Cr in March 2023 before decreasing to Rs. 542.19 Cr by March 2024. This suggests a strategic approach to leveraging and debt management in line with its operational needs.

Asset Base Expansion for Ipca Laboratories

Ipca Laboratories' total asset value has seen an upward trend, standing at Rs. 8,659.27 Cr in March 2024. Significant growth has been seen in investments, which more than quintupled to Rs. 2,243.56 Cr during the same period, reflecting strategic asset allocation.

The provided data offers a standalone balance sheet analysis of Ipca Laboratories without recommendations for trading.

When conducting stock screening, investors can glean insights from this data, integrating it with broader market analysis including NSE BSE indices and sector-based performance metrics.

Read More
X